论文部分内容阅读
目的:观察β-内酰胺酶抑制剂治疗小儿难治性肺炎的临床疗效。方法:将60例难治性肺炎患儿随机分为两组,观察组选用阿莫西林与克拉维酸合成剂或头孢哌酮与舒巴坦合成剂,对照组选用头孢哌酮或头孢曲松,同时两组采用相同的综合治疗措施,对两组治疗后退热时间、心力衰竭纠正时间及肺部湿性罗音消失时间进行比较。结果:观察组在治愈率、缩短退热时间和湿性罗音持续时间均优于对照组(P<0.01)。结论:小儿难治性肺炎多为耐药菌感染所致,应考虑产生超广谱β-内酰胺酶(ESBL)菌感染,选择β-内酰胺类抗生素与β-内酰胺酶抑制剂合成剂治疗肺炎,临床获得确切疗效。
Objective: To observe the clinical efficacy of β-lactamase inhibitor in the treatment of children with refractory pneumonia. Methods: Sixty children with refractory pneumonia were randomly divided into two groups. In the observation group, amoxicillin and clavulanic acid synthesizers or cefoperazone and sulbactam synthetic agents were used. In the control group, cefoperazone or ceftriaxone , While the two groups using the same comprehensive treatment measures, the two groups after treatment fever, heart failure correction time and lung wet rales disappear time were compared. Results: The cure rate, shortened antipyretic time and duration of wet rales in the observation group were better than those in the control group (P <0.01). CONCLUSIONS: Most intractable pneumonia in children is caused by drug-resistant bacterial infection. ESBL-producing bacteria should be considered for consideration. Β-lactam antibiotics and β-lactamase inhibitor synthesizer Treatment of pneumonia, clinically the exact effect.